Adaptive Biotechnologies Corporation (ADPT) exhibits 74.2% gross margins and -12.5% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 24.0x enterprise multiple and 6.9% implied options volatility.
Sustained 74.2% gross profitability converts into -20.6% operating margin and -12.5% ROIC, outpacing sector cost of capital.
ROIC: -12.5% // GM: 74.2%YoY revenue trajectory of +54.8% paired with -1.09% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +54.8% // FCF YLD: -1.09%Altman Z-Score of 6.32 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 6.32 // F-SCORE: 6/9Trading at 24.0x trailing P/E (26.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±6.9% implied move with a 0.93 put/call ratio around $28.00 max pain.
IMPL MOVE: ±6.9% // P/C: 0.93Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend -21.5% net margins.
NET MARGIN: -21.5% // D/E: 0.58x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ADPT & activate live FRED threshold breach alerts.